Sector News

Stryker acquires single-use device reprocessor Hygia Health Services

May 2, 2018
Life sciences

Stryker said today it acquired single-use-device reprocessor Hygia Health Services for an undisclosed amount.

Birmingham, Ala.-based Hygia has partnered with Kalamazoo, Mich.-based Stryker since 2015 to reprocess single-use devices, and Stryker said the acquisition will “further solidify the partnership.”

Stryker said that Hygia’s product portfolio of air transfer mattresses, fall alarms, ECG leads, cerebral-somatic sensors and infusor bags will help broaden its reprocessing offerings. Stryker said that it reprocessed approximately 3,000 single-use devices in 2017, with estimated savings of approximately $326 million.

“In line with our commitment to help hospitals and health systems increase the value their SUD reprocessing programs deliver, this acquisition will enhance our ability to deliver savings to our customers. Furthermore, our broader product portfolio will help customers elevate their sustainability goals and set a higher bar for sustainable healthcare delivery,” Stryker sustainability solutions prez Brian White said in a prepared statement.

Last week, Stryker saw shares fall slightly after it posted first quarter earnings that topped Wall Street expectations but saw sales shrink slightly.

By Fink Densford

Source: MassDevice

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach